Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BIIB with free AI briefings, catalyst countdowns, and dilution alerts.

BIIB · BIOGEN INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.3B Cash on Hand
CF+ Cash Runway
4.1% Short Interest
$268.26 Analyst Target (32)
Follow BIIB by email Get an email when BIIB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BIIB, unsubscribe in one click. Privacy

📣 What BIIB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nusinersen
FDA approved Dec 2016 · Spinraza
Muscular Atrophy, Spinal Phase 4 · NCT04488133 Completed
Tofersen
FDA approved Apr 2023 · Qalsody
Amyotrophic Lateral Sclerosis Phase 4 · NCT07223723 Active not recruiting
Peginterferon Beta-1A
FDA approved Aug 2014 · Plegridy
Multiple Sclerosis, Relapsing-Remitting Phase 3 · NCT03958877 Active not recruiting
Interferon Beta-1A
FDA approved May 1996 · Avonex
Multiple Sclerosis, Relapsing-Remitting Phase 3 · NCT03958877 Active not recruiting
Omaveloxolone
FDA approved Feb 2023 · Skyclarys
Friedreich Ataxia Phase 3 · NCT06953583 Active not recruiting
Natalizumab
FDA approved Nov 2004 · Tysabri
Multiple Sclerosis N/A · NCT05658497 Recruiting
Zuranolone
FDA approved Aug 2023 · Zurzuvae
Postpartum Depression N/A · NCT07398469 Recruiting
Diroximel Fumarate
FDA approved Oct 2019 · Vumerity
Multiple Sclerosis N/A · NCT05658497 Recruiting
Dimethyl Fumarate
FDA approved Mar 2013 · Tecfidera
Multiple Sclerosis N/A · NCT05658497 Recruiting
Litifilimab Subacute Cutaneous Lupus Erythematosus Phase 3 · NCT06044337 Enrolling by invitation
Lecanemab SC Early Alzheimer's Disease Phase 3 · NCT03887455 Active not recruiting
Lecanemab IV Early Alzheimer's Disease Phase 3 · NCT03887455 Active not recruiting
Felzartamab Immunoglobulin A Nephropathy (IgAN) Phase 3 · NCT06935357 Recruiting
Salanersen Muscular Atrophy, Spinal Phase 3 · NCT07444450 Recruiting
Diranersen Mild Cognitive Impairment Due to Alzheimer's Disease Phase 2 · NCT05399888 Active not recruiting
BIIB147 Amyotrophic Lateral Sclerosis Phase 1/2 · NCT07855211 Recruiting

Also used in these trials (approved or third-party drugs, not BIIB's own candidates): Tacrolimus Extended-Release, Ponesimod, Siponimod, Ofatumumab, Ocrelizumab, Glatiramer Acetate, Fingolimod Hydrochloride, Interferon Beta-1B, Alemtuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BIIB holds $1.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIIB files for a raise →

👥 Who Owns BIIB

Insiders 0.2% Institutions (1517 holders) 98.7% Public and other holders 1.1%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 18,294,524 12.38% 2026-06-30
Blackrock Inc. Institution (13F) 16,089,189 10.88% 2026-09-30
Primecap Management Company Institution (13F) 15,197,022 10.28% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 10,989,562 7.43% 2026-03-31
STATE STREET CORPORATION Institution (13G, 5%+) 7,570,589 5.12% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 6,572,163 4.45% 2026-09-30
Geode Capital Management, LLC Institution (13F) 4,507,404 3.05% 2026-09-30
Wellington Management Group, LLP Institution (13F) 3,458,781 2.34% 2026-09-30
Morgan Stanley Institution (13F) 2,506,411 1.70% 2026-09-30
Susan H Alexander
EVP Chief Legal Officer · +20,224 options
Insider 61,889 0.04% 2026-02-06
Caroline Dorsa
Director
Insider 31,002 0.02% 2025-06-17
Christopher Viehbacher
President and CEO, Director · +77,931 options
Insider 29,924 0.02% 2026-02-06

Share count 147,820,223 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-30
filed 2026-11-02
Grogan Jane
Option exercise (M) 695 – 4,753
2026-10-30
filed 2026-11-02
Grogan Jane
Tax withholding (F) 345 $253.62 4,408
2026-10-30
filed 2026-11-02
Grogan Jane
Option exercise (M) 695 – –
2026-10-02
filed 2026-10-05
Godbout Sean
Option exercise (M) 27 – 1,467
2026-10-02
filed 2026-10-05
Godbout Sean
Tax withholding (F) 8 $219.88 1,459

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-05-24 — NDA +3.1% -0.4% -0.8%
2026-04-03 LEQEMBI® IQLIK™ (lecanemab-irmb) NDA -6.6% -2.8% -2.5%

Browse all historical PDUFA outcomes →

Get the full BIIB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIIB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.